Published on : Jul 24, 2017
Albany, New York, July 24, 2017: Fatigue among training doctors is a serious public health concern; both for the health of the junior doctor and patients under their responsibility. Analysts have studied that 10% of people all around the world at any one time are suffering from persistent tiredness which could lead to mental distress. Due to this, treatment for fatigue is necessary. Market Research Hub (MRH) has recently broadcasted the latest study to its vast repository, which is titled as “Fatigue - Pipeline Review, H2 2017” and offers comprehensive information on the therapeutic under development for fatigue and overall pipeline landscape. The pipeline products described in this report have been analyzed on the basis of their development stage i.e. from pre-registration to discovery.
The first section of the report presents an overview of fatigue (central nervous system). This section highlights the development of therapeutics, pipeline products utilized in fatigue and a comparative analysis of these pipeline products. Fatigue, which is characterized by a state of awareness of a range of sickness, is usually associated with mental or physical weakness, or both. It is often accompanied by a peculiar sense of discomfort, a desire to rest, and a decline in motivation referred to as fatigue sensation.
As per the findings, more cases of fatigue have a mental than physical cause, according to collected data. Major signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite. There are so many causes of fatigue that pinpointing the exact cause can sometimes be long and scrutinizing. In addition to aspects of daily life, prescription medications and diseases, conditions and sicknesses both physical and psychological can cause symptoms of fatigue.
Moreover, the analysts have conducted an assessment of fatigue therapeutics on the basis of molecule type, target, route of administration, and mechanism of action. Drugs such as anamorelin hydrochloride, MRZ-9547, CTDP-001, BLI-1402, (lofepramine hydrochloride + phenylalanine), Caffeine and phenylbutyrate are studied in the report. With many new fatigue drugs in the pipeline, the market is expected to grow smoothly in the coming years.
Also, the therapeutics still under development by both universities and companies, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases have been presented. For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends, and their efforts to discover new therapeutics for fatigue. At present, key players involved in the therapeutic development are Aoxing Pharmaceutical Company Inc, Merz Pharma GmbH & Co KgaA. MultiCell Technologies Inc, BioLite Inc and Chronos Therapeutics Ltd.
Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230567
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org